R&D channel feed – Endpoints News

R&D channel feed

As controversy over childhood deaths simmers in the Philippines, Sanofi balks at a Dengvaxia reimbursement

8 years ago

Skeptics pounce after Bristol-Myers scores an early hit on Opdivo-Yervoy combo for lung cancer

8 years ago

AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints

8 years ago

Think your odds of R&D success are miserable? MIT’s Andrew Lo might have a surprise for you

8 years ago

Puma touts its latest advances in a basket trial for Nerlynx, as Europeans appear ready to reject the drug

8 years ago

Roche silently scraps two one-time blockbuster hopefuls as $725M Seragon deal craters

8 years ago

Vertex execs whip up a cheer from the analysts after hedging their bet by picking their two top triples for PhIII

8 years ago

Analysis: Pfizer tallies an impressive array of late-stage catalysts for cancer, gene therapies and more

8 years ago

Focused on blockbuster indications, Sage touts evidence that 217 could work on insomnia

8 years ago

Brain damage cases force an FDA hold on Bellicum's lead cell therapy -- shares tank

8 years ago

Counting its remaining cash, Vical axes 40 staffers and circles wagons around two Phase II assets

8 years ago

Eyeing a multibillion-dollar market, Shire snags preclinical IVIg rival from AB Biosciences

8 years ago

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

8 years ago

Aradigm completes disastrous regulatory run as FDA slaps down Linhaliq application

8 years ago

Behind the deal spree, Celgene continues to cautiously explore neurosciences

8 years ago

Trailing GSK, AstraZeneca offers an encouraging look at PhIII data for three-in-one COPD inhaler

8 years ago

Takeda and Zinfandel write off yet another Alzheimer’s PhIII after Actos fails a key interim test

8 years ago

Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer's

8 years ago

GW on fire: PhIII epilepsy data signals success ahead for first CBD drug

8 years ago

Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal

8 years ago

Pfizer’s latest copycat could put the squeeze on Roche — again

8 years ago

Reckoning the potential of CRISPR/Cas9 tech, NIH launches $190M genome editing research initiative

8 years ago

Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data

8 years ago

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

8 years ago

First page Previous page 279 280 281282283 284 285 Next page Last page